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Proteins undergo a remarkable variety of posttranslational modiﬁcations, with more than 200 distinct modiﬁcations
identiﬁed to date. Increasing evidence suggests that many proteins bear multiple, distinct modiﬁcations, and the
ability of one modiﬁcation to antagonize or synergize the deposition of another can have signiﬁcant biological
consequences. Here, we illustrate the importance of posttranslational modiﬁcations within the context of
transcriptional regulation, and we oﬀer a perspective on the emerging role of combinatorial networks of
modiﬁcations. Finally, we discuss the potential for chemical approaches to transform our understanding
of the ﬁeld.
Introduction
A fundamental tenet of biochemistry is that proteins are com-
posed of 20 basic building blocks. Given the limited range of
chemical functionality present in the amino acid side chains,
the diversity of protein structure and function is truly extra-
ordinary. In reality, the situation is not so simple: Nature uses
covalent modiﬁcations to proteins to complement and expand
its chemical repertoire. Indeed more than 200 distinct post-
translational modiﬁcations (PTMs) have been identiﬁed to date,
and the number and variety of modiﬁcations continue to grow
(Fig. 1).1 Covalent modiﬁcations to proteins have been shown to
have a profound impact at both the molecular and cellular level.
For instance, the introduction of phosphoryl, glycosyl and
other chemical groups can mediate the activity of a protein,
aﬀect its subcellular localization, or modulate its interaction
with other macromolecules. At a more global level, PTMs have
been shown to inﬂuence cellular events such as gene expression,
cell cycle progression and programmed cell death.
With an increased understanding of PTMs has come the
exciting observation that many proteins undergo multiple,
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distinct chemical modiﬁcations. These discoveries point to the
existence of complex combinatorial networks of PTMs with the
potential to modulate diﬀerent biological outcomes. Sorting
out this ‘molecular switchboard’ of posttranslational events
should reveal novel mechanisms for the control of biological
systems and promises to open up new avenues for the explor-
ation and manipulation of processes such as gene expression,
signal transduction and cell-cycle progression. Here, we oﬀer a
perspective on this emerging area of research. Rather than
provide an exhaustive survey, we have chosen to highlight the
importance of PTMs in the speciﬁc context of transcription. In
addition, we review examples of combinatorial networks of
PTMs and discuss the potential for chemical approaches to
transform our understanding of the ﬁeld.
The process of transcription
The coordinated expression of speciﬁc genes is one of the most
fundamental, exquisitely regulated processes in biology.2 For
instance, the spatial and temporal expression of unique sets of
genes diﬀerentiates a brain cell from a heart cell and enables
each to perform its highly specialized functions. In the event of
malfunction, aberrant gene expression can lead the cell down
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Fig. 1 Some examples of posttranslational modiﬁcations.
the path to cancer, neurodegenerative disorders and other dis-
eases. Not surprisingly, organisms have evolved intricate mech-
anisms to achieve control and speciﬁcity over gene expression
patterns. The molecular machinery responsible for gene tran-
scription in eukaryotes consists of RNA polymerase II (RNAP
II) and over 80 distinct regulatory proteins, which together
initiate or suppress RNA synthesis at sites throughout the
genome. Among the best understood factors are the sequence-
speciﬁc transcription factors, which initiate gene-speciﬁc tran-
scription and comprise an estimated 5–10% of the genes in the
human genome. In addition, general transcription factors,
along with coactivators and corepressors, assist the polymerase
with catalysis and recognition of the DNA promoter sequence.
Finally, the chromatin remodeling complexes help the tran-
scriptional machinery to navigate through tightly packaged
DNA–protein complexes known as chromatin.
While the basic molecular components of the transcriptional
machinery have been well characterized, the mechanisms by
which they orchestrate distinct patterns of gene expression are
only now being illuminated. Studies suggest that various com-
ponents of the machinery may assemble in a combinatorial
manner that is dependent on the status of the cell. However, the
speciﬁc assemblies that arise at a given time or place, and the
signals that trigger their assembly and disassembly, are not well
understood. Recent studies suggest that covalent modiﬁcations
may play critical roles in various stages of the transcriptional
process, thereby facilitating speciﬁcity and temporal control.
Gene-speciﬁc transcription: posttranslational
modiﬁcation of transcription factors
Protein phosphorylation is widely recognized as a common
mechanism for regulating transcription factors, and this mech-
anism is beautifully conserved throughout evolution (reviewed
in ref. 3). In addition to phosphorylation, however, transcrip-
tion factors and coactivators are subject to a host of other
PTMs. Here, we consider the impact of PTMs in the context of
two case studies: CREB (cAMP-responsive element binding
protein) and p53.
Regulation of CREB by PTMs
CREB, the ﬁrst transcription factor shown to be modiﬁed by
phosphorylation, plays a central role in the regulation of
glucose homeostasis, growth-factor-dependent cell survival and
memory storage.4 Addition of a phosphoryl group to a single
site, Ser133, activates CREB-dependent transcription by pro-
moting the association of CREB with the coactivator CBP
(CREB binding protein or its relative p300; Fig. 2). NMR stud-
ies have shown that the kinase-inducible domain of CREB
undergoes a structural transition from random-coil to alpha-
helix upon phosphorylation and CBP interaction (Fig. 3). Once
assembled, the CREB–CBP complex is believed to stimulate
gene expression through the recruitment of an active RNAP II
complex and the remodeling of chromatin via histone
acetylation. Thus, phosphorylation of Ser133 serves as a key
molecular switch to activate CREB.
Intriguingly, a wide variety of stimuli, including cyclic AMP,
phosphoinositol, nerve growth factor, and KCl-induced
depolarization of neurons, leads to phosphorylation of Ser133
with comparable stoichiometry and kinetics. Consistent with
this observation, CREB is a substrate for numerous protein
kinases, including 90 kDa ribosomal S6 kinase (pp90RSK),
Fig. 2 Domain structure of CREB. Phosphorylation at Ser133
activates CREB-dependent transcription by recruiting the coactivator
CBP/p300. Q1 and Q2, glutamine-rich domains; KID, kinase-inducible
domain; bZIP, DNA-binding leucine zipper domain.
2 O r g .  B i o m o l .  C h e m . , 2 0 0 4 , 2,  1 – 7
Pu
bl
ish
ed
 o
n 
02
 D
ec
em
be
r 2
00
3.
 D
ow
nl
oa
de
d 
on
 1
9/
05
/2
01
5 
00
:5
4:
36
. 
View Article Online
protein kinase C (PKC), mitogen- and stress-activated protein
kinase (MSK-1), mitogen-activated protein kinase-activated
protein kinase-2 (MAPKAP-2) and Ca2, calmodulin-depend-
ent protein kinases (CaMK) II and IV. Eﬀorts to understand
how CREB distinguishes between distinct cellular inputs have
led to the discovery of additional covalent modiﬁcations that
impact CREB activity.
Functional roles for two other phosphorylation sites, Ser142
and Ser143, have been uncovered.4–6 Phosphorylation at Ser142
by CaMKII prevents formation of the CREB–CBP complex
in vitro and blocks the activation of target genes in transfected
mammalian cells. On the other hand, Ser142 phosphorylation
has also been linked to the positive regulation of CREB activity.
For instance, Gau et al. demonstrated that both Ser142 and
Ser133 participate in resetting of the circadian clock using
a mouse mutant lacking the Ser142 phosphorylation site
(S142A).5 Down-regulation of the clock-keeping genes, c-fos
and mPer1, was observed in the mouse mutant, suggesting
that phosphorylation of Ser142 activates CREB-dependent
transcription. Studies by Kornhauser et al. lend further support
to a stimulatory role for Ser142.6 In particular, the triply phos-
phorylated form of CREB was required for eﬀective calcium
depolarization-induced transcription in neurons. These studies
reveal an interesting interplay among the three sites and suggest
that distinct combinations of PTMs may be capable of trigger-
ing speciﬁc programs of gene expression.
In addition to phosphorylation, CREB has been shown to be
regulated by O-GlcNAc glycosylation, the covalent modiﬁ-
cation of serine and threonine residues by β-N-acetylglucos-
amine (Fig. 4).7 The O-GlcNAc modiﬁcation is present in all
higher eukaryotic organisms from C. elegans to man. It has
been shown to be ubiquitous, inducible and highly dynamic,
suggesting a regulatory role analogous to phosphorylation.8
Glycosylation of CREB occurs at two sites within the trans-
activation domain. Addition of the sugar disrupts the
interaction between CREB and TAFII130, a component of the
transcriptional machinery, and hinders the ability of CREB to
activate gene transcription in vitro. Thus, glycosylation may
function as a ‘brake’ to repress the activity of CREB and coun-
teract the stimulatory eﬀect of phosphorylation. Consistent
with a role for O-GlcNAc in transcriptional repression, the
enzyme that catalyzes the modiﬁcation (O-GlcNAc glyco-
syltransferase, OGT) has been shown to associate with the
transcriptional repressor protein mSin3A and thereby syn-
ergistically suppress transcription.8 Elucidating the dynamic
interplay between glycosylation and phosphorylation of CREB
and the extracellular stimuli that modulate O-GlcNAc glyco-
sylation levels should provide additional insight into the
physiological signiﬁcance of this unusual modiﬁcation.
Fig. 3 NMR structure of the complex of the kinase-inducible domain
of CREB (yellow) with the KIX domain of CBP (cyan). Ser133
is located at the amino terminus of helix αB and forms an ion pair
with Lys652 and a hydrogen bond with Tyr658 of CBP. Together,
these two contacts account for nearly half the free energy of com-
plex formation. (Copyright permission from: Nat. Rev. Mol. Cell Biol.
http://www.nature.com/) Recently, CREB was also shown to undergo acetylation
at three lysine residues within the kinase inducible domain.9
While the importance of histone acetylation has been recog-
nized for nearly 30 years, recent studies have revealed much
broader roles for this modiﬁcation than were suspected
previously. The addition of an acetyl group has been shown to
modulate a number of functional properties of transcription
factors. For instance, acetylation can decrease the binding
of transcription factors to DNA promoters, attenuate
transcription by disrupting transcription factor–coactivator
complexes or cause nuclear sequestration of transcription
factors. In the case of CREB, mutation of the three acetylated
lysine residues to alanine or arginine markedly enhanced
CREB-dependent gene expression. While Lu et al. have
proposed that acetylation enhances the transactivation poten-
tial of CREB, the precise functional impact of acetylation
warrants further study given the considerable structural
diﬀerences between acetylated lysine and the alanine/arginine
mutations.
As improved methods for studying PTMs are developed,
additional modiﬁcations will undoubtedly enter into the arena.
Continued investigation into the functional roles of these
modiﬁcations and the cross-talk between them is expected to
provide a deeper understanding of CREB-mediated biological
processes such as neuronal survival, glucose homeostasis and
memory storage.
Regulation of p53 by PTMs
The transcription factor p53 plays a critical role in suppressing
tumor development by initiating a program of cell cycle arrest
and programmed cell death (apoptosis) in abnormal or stressed
cells.10 Apoptosis can prevent cancerous cells from prolifer-
ating, but malignancy is often associated with malfunctioning
pro-apoptotic machinery in cells. In fact, half of all human
cancers are associated with a mutation within the p53 gene,
while many others show deﬁciency in the p53-mediated
pathway.
Due to its dramatic consequences for cellular function, the
activity of p53 must be tightly regulated. Under conditions of
normal cell growth, p53 activity is tightly suppressed, while
DNA damaging agents (genotoxic stimuli) lead to rapid induc-
tion of p53 to initiate programmed cell death. This intricate
regulation involves a plethora of posttranslational modiﬁ-
cations, which include at least 18 distinct sites in the human
form of the protein. Elucidating the precise roles of each modi-
ﬁcation is beginning to reveal how this important transcription
factor responds to diverse environmental cues. Moreover,
insights into the mechanisms of p53 regulation are yielding
new and exciting drug targets for cancer therapy (reviewed in
ref. 11).
Fig. 4 Illustration of the potential interplay between dynamic
O-GlcNAc glycosylation and phosphorylation.
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Fig. 5 Domain structure of p53 and sites of phosphorylation (P), acetylation (Ac) and sumoylation (S) in response to DNA damaging events
(e.g. UV and γ-radiation, and the DNA strand breaker camptothecin); cellular stress (e.g. oxygen deprivation mimicked by deferoxamine mesylate);
transcriptional inhibition induced by the RNAP II inhibitor actinomycin D. NLS, nuclear localization signal domain; TET, tetramerization domain;
REG, regulation of DNA-binding domain.
Various toxic stimuli induce both the accumulation and
activation of p53, including genotoxic radiation, inhibitors of
DNA replication and transcription, as well as osmotic and heat
shock (Fig. 5).12 One of the primary ways by which cellular
stress is relayed to p53 is via kinase pathways. Indeed, inducible
phosphorylation of p53 has been observed at 9 sites within
the N-terminal region of the protein and at 2 sites within the
C-terminal region, with distinct phosphorylation events medi-
ated by diﬀerent kinases and induced by particular stimuli. For
example, phosphorylation of Ser15 is strongly induced by DNA
damaging agents such as UV and γ-radiation, cisplatin and
camptothecin, but it is not induced in response to the RNA
polymerase II inhibitor actinomycin D, which is nonetheless
known to activate p53. While both UV and γ-radiation stimu-
late the rapid phosphorylation of Ser15 within 1–2 h, phos-
phorylation of Ser 46, in contrast, is signiﬁcantly delayed.13 The
kinase that phosphorylates Ser46 in response to UV radiation
(homeodomain-interacting protein kinase 2, HIPK2) cannot
phosphorylate Ser46 following γ-radiation, suggesting that
these two types of DNA damaging events lead to divergent
pathways.14 Interestingly, phosphorylation of Ser 46 by HIPK2
is necessary but not suﬃcient to induce apoptosis of target
cells. Indeed, UV radiation leads to phosphorylation not only
of Ser15 and Ser46, but also of Ser6, Ser9, Ser20 and Ser37.
Thus, multiple concerted phosphorylation events appear to be
required for UV-induced apoptosis.
The mechanisms by which phosphorylation induces p53
accumulation and activity are only beginning to be understood.
In many cases, phosphorylation appears to be linked to protein
stability.12 In unstressed cells, p53 accumulation is prevented by
association of the N-terminus of p53 with the ubiquitin ligase
MDM2. MDM2 decorates numerous p53 lysines with the
76-residue protein ubiquitin, a signal that targets p53 for
rapid degradation. Several phosphorylation sites within the
N-terminus of p53 have been shown to disrupt the speciﬁc
interaction between p53 and MDM2. For example, phos-
phorylation of Ser20 appears to be necessary for stabilizing p53
in vivo in response to UV and γ-radiation, and signiﬁcantly
disrupts binding to MDM2 in vitro. Moreover, the kinase that
phosphorylates Ser20 in vitro (checkpoint kinase 2) was shown
to be required for p53 stabilization in response to γ-radiation.
Likewise, phosphorylation of Thr18 directly disrupts the inter-
action of p53 with MDM2 in vitro.15 Intriguingly, the authors
found that phosphorylation at Thr18 in response to DNA dam-
age was ablated in a mutant missing Ser15. Indeed, in vitro
attempts to phosphorylate Thr18 were only successful if Ser15
was previously phosphorylated. These data highlight the excit-
ing interplay of PTMs at work in the p53 N-terminus during
stabilization and activation.
In contrast to phosphorylation events at the N-terminus,
modiﬁcations close to the C-terminus inﬂuence the tran-
scriptional activity of p53 rather than its stabilization. Many
studies suggest that the C-terminal region acts as a negative
regulator of p53 transactivation, primarily by inhibiting
sequence-speciﬁc DNA binding. For instance, phosphorylation
of Ser392, which is induced upon genotoxic radiation, activates
sequence-speciﬁc DNA binding in vitro.10 Similarly, phos-
phorylation of Ser315 also enhances sequence-speciﬁc DNA
binding in vitro, and mutation of this site to alanine reduces the
transcriptional activity of p53 in vivo.12 Notably, phosphoryl-
ation at Ser315 as well as Ser33 and Thr81 promotes binding of
p53 to the peptidyl-prolyl isomerase Pin1. The consequence
of Pin1 binding is a conformational change in p53 that has a
stimulatory eﬀect on p53 activity in vivo.16
In addition to phosphorylation, acetylation also plays a
pivotal role in p53 function. Acetylation at multiple lysine resi-
dues in the C-terminus is induced in vivo in response to virtually
all cellular stresses that activate p53 and is mediated by the
acetyltransferase activity of CBP/p300 and the closely-related
CBP/p300-associated factor (PCAF) in vitro. Interestingly,
acetylation can also be triggered by phosphorylation, suggest-
ing an interplay between the two modiﬁcations. Speciﬁcally,
recent studies indicate that phosphorylation of Ser46 by
HIPK2 is necessary for CBP-mediated acetylation at Lys382,
which in turn augments p53 activation in response to UV
radiation.14 Growing evidence suggests that acetylation, like
phosphorylation, may play multiple roles in stabilizing and
activating p53. Modiﬁcation by CBP/p300 and PCAF has been
shown to signiﬁcantly increase p53 sequence-speciﬁc binding to
DNA in vitro. Additionally, acetylation of speciﬁc lysine resi-
dues in vitro has been shown to block ubiquitination at those
sites as well as nearby non-acetylated lysines.17 Moreover,
the same authors show that acetylation signiﬁcantly extends the
half-life of p53 in cells. Finally, recent evidence suggests that the
primary role of acetylation may be to activate p53-mediated
transcription by recruiting coactivators and histone acetyl-
transferases to p53-responsive genes.
Acetylation and phosphorylation are only two of the best-
characterized modiﬁcations that impact p53 function. The
transcription factor has been demonstrated to bear numerous
other modiﬁcations, including ubiquitination, sumoylation (the
addition of the small ubiquitin-like protein SUMO), O-Glc-
NAc glycosylation and ribosylation.10 While these other modi-
ﬁcations will not be considered in detail here, the addition of
ubiquitin plays a particularly important role in p53 stability.17
Interestingly, an early candidate for a p53-stabilizing drug, CP-
31398, identiﬁed by Pﬁzer, functions in vivo by inhibiting the
ubiquitination of p53. Although the mechanism by which CP-
31398 inhibits ubiquitination is unclear, CP-31398 represents a
promising prototype for cancer therapy.18 While many more
modiﬁcations of p53 remain to be elucidated, it is clear that a
complex network of posttranslational modiﬁcations permits
the ﬁne-tuned regulation of this vital transcription factor.
Unraveling of the DNA: posttranslational
modiﬁcations of histone proteins
The expression of genes in higher organisms depends critically
on the accessibility of the DNA being transcribed. In the
nucleus, DNA is packaged around a set of histone proteins
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(H2A, H2B, H3 and H4), which together with histone H1 and
other non-histone proteins, maintain chromatin in its con-
densed state, inaccessible to the transcriptional machinery.19 In
order for transcription to proceed, the condensed chromatin
must be unraveled. While the precise mechanisms behind this
process are not fully understood, the covalent modiﬁcation of
histones has emerged as a key determinant. Protruding from
the nucleosomes of chromatin are the charged N-terminal
“tails” of histones. These ﬂexible tails contain several residues
that are subject to a diverse array of PTMs, including acetyl-
ation, phosphorylation, methylation and ubiquitination. Dis-
tinct histone modiﬁcations or “marks” have been linked to
speciﬁc transcriptional states. A set of proteins appears to
recognize the marks, thereby dictating dynamic transitions
between transcriptionally active or repressed chromatin states.
Thus, the presence of a PTM may specify a ‘code’ that deter-
mines a distinct regulatory outcome.
As histone modiﬁcations have been extensively reviewed,19 we
highlight here only a few examples. Acetylation of histones H3
and H4 at speciﬁc lysine residues has been correlated with tran-
scriptional activity, and accordingly, acetyl groups are select-
ively recognized by coactivators containing bromo-domains
and intrinsic histone acetyltransferase activity (Fig. 6). Consist-
ent with a stimulatory role for many acetyl marks, the histone
deacetylases (HDACs) that catalyze the reverse reaction have
been linked to transcriptional repression. Although less is
known about histone phosphorylation, the addition of a
phosphoryl group to Ser10 of histone H3 has emerged as a
fundamental player in both transcriptional activation and
chromosomal condensation during mitosis. For example,
dramatic increases in Ser10 phosphorylation are induced at
active loci during the heat-shock response in Drosophila
melanogaster. More recently, the discovery of lysine and argin-
ine methyltransferases that are targeted to speciﬁc promoters
has revealed an exciting regulatory role for histone methylation.
Methylation of Lys9 of histone H3 speciﬁcally recruits a well-
known repressor protein, HP1, to silent heterochromatic sites.
On the other hand, methylation of Lys4 has been associated
with active genes on euchromatin, and arginine methylation of
histone H3 is present only when nuclear receptor-regulated
promoters are active. Methylation thus can exert opposing
eﬀects on transcriptional regulation, depending on the speciﬁc
residue involved.
The story becomes more fascinating when one considers the
interplay between various histone modiﬁcations and the poten-
tial for combinatorial diversity. Speciﬁc patterns and temporal
sequences of modiﬁcation events have been observed in vivo,
and the presence of a given modiﬁcation can facilitate or block
the presence of a second modiﬁcation elsewhere on the same
histone.19 In the case of histone H3, for example, phosphoryl-
ation of Ser10 enhances acetylation of Lys14 by Gcn5 in vitro
and precedes Lys14 acetylation at speciﬁc promoters in vivo.
Furthermore, deacetylation of Lys14 precedes and is required
Fig. 6 Posttranslational ‘marks’ on the amino terminus of histone H3.
Modiﬁcations linked to transcriptional activation are shown in green;
repressive marks are indicated in red. Potential synergistic interactions
are illustrated as connected arrows, while antagonistic interactions are
shown as a blocked oval line. P, phosphorylation; Ac, acetylation; Me,
methylation.
to facilitate Lys9 methylation by the histone methyltransferase
Clr4. Other studies have shown that phosphorylation of Ser10
blocks Lys9 methylation in vitro, and conversely, methylation of
Lys9 prevents Ser10 phosphorylation both in vitro and in vivo.
Thus, speciﬁc histone modiﬁcations can function to enhance or
antagonize one another, providing a mechanism to induce and
stabilize speciﬁc pairings.
A prediction of the histone code hypothesis is that the sum of
the modiﬁcations, both in kind and number, will specify distinct
biological outcomes, such as gene activation versus gene silen-
cing or more globally, cell proliferation versus cell diﬀeren-
tiation. It remains to be seen, however, whether each modiﬁ-
cation pattern will encode a unique downstream consequence
or whether certain modiﬁcations will instead tune the speci-
ﬁcity, duration or magnitude of the transcriptional response.
Nonetheless, the covalent modiﬁcation of histones clearly
encodes functional information essential for chromatin-
mediated processes.
RNA polymerase II and the potential CTD code
The transcription of genes is a multi-staged process, which
depends on the eﬀective recruitment by transcription factors of
coactivators, RNAP II and general transcription factors to
target genes. As we have seen, all of the central players in this
process require posttranslational control for stability or
protein–protein interactions, and RNAP II is no exception.
Covalent modiﬁcations to the carboxy-terminal “CTD”
domain of the largest subunit of RNAP II play an essential role
in governing the transcriptional initiation, elongation and
termination stages of transcription.2 In mammals, the CTD is
composed of 52 repeats of the consensus heptapeptide Tyr-Ser-
Pro-Thr-Ser-Pro-Ser. As the transcriptional initiation complex
is formed, the CTD remains unphosphorylated (Fig. 7). Partial
phosphorylation of the CTD is associated with disruption of
RNAP II-promoter interactions (promoter clearance) and the
recruitment of enzymes that cap the 5 end of the nascent
RNA. Further phosphorylation promotes transcript elongation
and the recruitment of the pre-mRNA splicing machinery. At
the ﬁnal stages of transcription, the CTD recruits protein
factors for transcript cleavage and 3 polyadenylation. Thus,
phosphorylation of the CTD plays a critical role during all
phases of transcription by assembling a multitude of necessary
factors.
But how does the CTD recruit distinct factors during the
course of the transcriptional process? One mechanism may
involve diﬀerential phosphorylation of the CTD tail. Notably,
phosphorylation of the CTD dynamically changes over the
course of transcription.2 Phosphorylation of Ser5 in the CTD
motif is observed between transcription initiation and pro-
moter clearance, whereas phosphorylation of Ser2 occurs only
during the elongation phase of transcription. These changes in
phosphorylation may recruit distinct factors required for the
respective stages of transcription.
Indeed, in yeast, the phosphorylation state of the CTD
speciﬁcally mediates interactions with a transcription elon-
gation complex (PAF), which in turn coordinates tran-
scriptional regulatory signals and the posttranslational
modiﬁcation of chromatin.20 PAF recruits the yeast Set1 and
Set2 histone methyltransferases to the coding regions of DNA.
As histone methylation mediated by Set1 is enriched in the 5
region of transcribed genes, it is speculated that histone tails
modiﬁed by Set1 may serve as docking sites for various RNA
processing complexes during the initiation phase of transcrip-
tion. In contrast, Set2 appears to function as an elongation
factor, with histone tails methylated by Set2 providing potential
docking sites for factors involved in later stages of elongation
and termination.
Interestingly, the CTD of RNAP II has also been shown
to undergo O-GlcNAc glycosylation when present in the
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Fig. 7 Changes in the phosphorylation state of the carboxy-terminal domain (CTD) of RNAP II during the initiation and elongation phases of
transcription coordinate the transcription process. The initiation phase is associated with phosphorylation of Ser5 of the CTD and the recruitment
of capping factors to the nascent RNA transcript. Elongation is associated with additional phosphorylation of the CTD at Ser2 and recruitment of
factors involved in elongation and processing of the nascent RNA. O-GlcNAc glycosylation may oppose phosphorylation by preventing tran-
scriptional activation.
unphosphorylated state in vivo.8 Studies suggest that glyco-
sylation may function in opposition to phosphorylation. For
instance, synthetic CTD peptides that undergo glycosylation at
Thr4 of each CTD repeat cannot be phosphorylated by the
TFIIH kinase CDK7.
21 Conversely, phosphorylated peptides
are not substrates for the O-GlcNAc glycosyltransferase OGT,
even though the two primary sites of modiﬁcation are distinct.
A functional relationship between OGT and RNAP II has been
further suggested by recent observations that RNAP II and
OGT form a complex in vivo.8 One implication of these studies
is that glycosylation of RNAP II may prevent transcriptional
activation and elongation, consistent with a general role for
O-GlcNAc in transcriptional repression (see also discussion of
CREB). It will be interesting to establish whether OGT repre-
sents a bona-ﬁde transcriptional repressor in this context and to
uncover mechanisms for relieving this inhibition.
Future directions
The process of transcription vividly demonstrates the complex
and ﬁnely tuned role of PTMs in controlling biological pro-
cesses. Further eﬀorts to uncover novel modiﬁcation forms, to
elucidate the physiological functions of PTMs, and to explore
their dynamic regulation in cells should enhance our under-
standing of this important regulatory manifold.
Growing interest in these modiﬁcations has spurred the
development of exciting methodologies to tackle the study of
PTMs.22 For example, multidimensional protein identiﬁcation
technology (MudPIT), which uses multiple chromatographic
steps coupled to mass spectrometry, has enabled global studies
of posttranslationally modiﬁed proteins in yeast. Chemical
derivatization methods and metal ion aﬃnity chromatography
combined with mass spectrometry have facilitated the enrich-
ment of modiﬁed peptides and the sequencing of modiﬁcation
sites. Moreover, complementary approaches such as ‘bump-
hole’ type strategies have identiﬁed novel physiological sub-
strates of protein kinases.23 Most of these approaches, however,
have been most successful when applied to small sets of phos-
phorylated proteins in speciﬁc functional contexts. As such, a
major obstacle to the study of PTMs remains the paucity of
methods for tracking the wide variety of modiﬁcations in vivo.
One complication lies in the nature of PTMs themselves – i.e.,
most modiﬁcations are ﬂeeting, present in low cellular abund-
ance, and/or restricted to speciﬁc cell types or subcellular com-
partments. The need for robust methods to detect PTMs rapidly
and with requisite sensitivity represents an opportunity for
chemists to extend existing strategies and to develop new
technologies.
The study of PTMs will likely reveal previously unknown
modes for the regulation of protein function. Approaches that
allow for the homogeneous incorporation of modiﬁed amino
acids into proteins will be essential for elucidating the diverse
functional roles of PTMs.24 In particular, the incorporation of
unnatural amino acids via nonsense suppression and the semi-
synthesis of proteins via expressed protein ligation will continue
to be invaluable tools for understanding structure–activity rel-
ationships. Moreover, the identiﬁcation of speciﬁc modiﬁcation
sites will enable further dissection of the precise functional roles
of individual modiﬁcations using genetic approaches.
The potential for covalent modiﬁcations to be dynamically
regulated in response to extracellular signals raises fascinating
questions. It will be important to determine which modiﬁ-
cations are inducible and to elucidate the enzymes and path-
ways involved. In contrast to kinase pathways, the signaling
cascades leading to other modiﬁcations such as acetylation,
glycosylation and methylation are less well understood. Will
histone demethylases be discovered, for example? What cellular
signals will stimulate a particular covalent modiﬁcation or
pattern of modiﬁcations? Notably, some PTMs, including
deacetylation by the NAD-dependent sirtuin enzymes and
O-GlcNAc glycosylation, have been shown to respond directly
to metabolic cues. Thus, further insights will be gleaned by
investigating PTMs in various physiological or pathological
contexts. For such studies, the synthesis of modiﬁed peptides
and the generation of selective antibodies should prove to be
invaluable tools. Just as phospho-speciﬁc antibodies have
expanded our understanding of kinase pathways, anti-
bodies against other PTMs should enable the levels of speciﬁc
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modiﬁcations to be monitored in response to various stimuli.
Moreover, advances in quantitative mass spectrometry analysis
and approaches that allow modiﬁcation events to be monitored
in living cells via ﬂuorescence microscopy should provide
further insight into the dynamic regulation of PTMs.25
Lastly, understanding the interrelationship between multiple
diﬀerent modiﬁcations will be critical for unraveling the com-
binatorial ‘code’ of PTMs. The ability of one modiﬁcation to
antagonize or synergize the deposition of another modiﬁcation
can have important biological consequences, and dynamic tran-
sitions among various modiﬁcation states could serve to regu-
late the spatial and temporal behavior of proteins. At present, it
remains to be seen what fraction of the protein molecules will
experience a given set of modiﬁcation events. In this regard, the
development of new approaches to detect low levels of modiﬁ-
cations in cells and to isolate proteins bearing discrete modiﬁ-
cations will be essential. Ultimately, eﬀorts to sort out the
‘molecular switchboard’ may lead to novel insights and modes
for manipulating gene expression and other important bio-
logical processes.
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